XML 65 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Employee Benefits and Stock Compensation (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation
The impact of share-based compensation on the Company’s financial results is presented below:
For the Year Ended December 31,
(In thousands)202420232022
Share-based compensation expense1
$13,744 $13,440 $11,155 
Income tax benefit$(3,483)$(3,406)$(2,827)
1 Excludes $10.3 million in 2023 and $10.4 million in 2022 associated with replacement awards granted in bank acquisitions.
Schedule of Unrecognized Compensation Cost, Nonvested Awards
The total unrecognized compensation cost and the weighted-average period over which unrecognized compensation cost is expected to be recognized related to non-vested share-based compensation arrangements at December 31, 2024 is presented below:
(In thousands)Unrecognized
Compensation
Cost		Weighted-Average Period Remaining (Years)
Restricted stock awards$16,339 1.80
Restricted stock units6,829 2.21
Total$23,168 1.92
Schedule of Nonvested Share Activity
A summary of the status of the Company’s non-vested RSAs as of December 31, 2024, and changes during the year then ended, is presented below:
Restricted
Award
Shares		Weighted-Average Grant-Date Fair Value
Non-vested at January 1, 2024763,212 $27.45 
Granted613,534 25.00 
Forfeited/Canceled(78,272)26.71 
Vested(340,952)28.78 
Non-vested at December 31, 2024957,522 $25.47 
A summary of the status of the Company’s non-vested RSUs as of December 31, 2024, and changes during the year then ended, is presented below:
Restricted
Award
Units		Weighted-Average Grant-Date Fair Value
Non-vested at January 1, 2024383,701 $29.31 
Granted260,999 25.75 
Forfeited/Canceled(40,208)31.00 
Vested(82,966)36.52 
Non-vested at December 31, 2024521,526 $26.25 
Schedule of Restricted Stock and Restricted Stock Units Activity
Information regarding restricted stock awards during each of the following years is presented below:
For the Year Ended December 31,
202420232022
Weighted-average grant date fair value$25.00 $24.57 $33.08 
Fair value of awards vested1
$9,813 $8,156 $6,923 
1Based on grant date fair value, in thousands.
Information regarding restricted stock units during each of the following years is presented below:
For the Year Ended December 31,
202420232022
Weighted-average grant date fair value$25.75 $22.84 $34.11 
Fair value of awards vested1
$3,030 $1,997 $2,305 
1Based on grant date fair value, in thousands.
Schedule of Stock Option Valuation Assumptions
For the Year Ended December 31,
 202420232022
Risk-free interest ratesN/A4.25 %2.21 %
Expected dividend yieldN/A2.45 %1.95 %
Expected volatilityN/A64.32 %32.09 %
Expected lives (years)N/A1.81.0
Schedule of Stock Options Roll Forward
A summary of the Company’s stock options as of December 31, 2024, and changes during the year then ended, is presented below:
 OptionsWeighted-Average Exercise Price
Outstanding at January 1, 2024823,963 $20.48 
Granted— — 
Exercised(185,606)13.31 
Expired(17,715)30.04 
Outstanding and Exercisable at December 31, 2024
620,642 $22.38 
Weighted-Average Remaining Contractual Term (Years)2.70
Aggregate Intrinsic Value (000s)
$3,933 
Schedule of Stock Option Activity
The following table presents information related to stock options during each of the following years:
For the Year Ended December 31,
202420232022
Weighted-average grant date fair valueN/A$12.63 $14.28 
Intrinsic value of stock options exercised, in thousands$2,487 5,969 8,860 
Schedule of Employee Stock Purchase Plan Activity
 202420232022
ESPP shares purchased32,840 35,630 20,972 
Weighted-average employee purchase price$24.42 $22.56 $30.76